US2020016081A1PendingUtilityA1

Drug loaded microspheres for post-operative chronic pain

54
Assignee: COVIDIEN LPPriority: Sep 26, 2014Filed: Sep 25, 2019Published: Jan 16, 2020
Est. expirySep 26, 2034(~8.2 yrs left)· nominal 20-yr term from priority
Inventors:Rachit OhriGary R. StrichartzPhillip Blaskovich
A61P 29/00A61P 25/04A61P 25/00A61P 23/02A61K 31/445A61K 9/0024A61K 9/1647
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A microsphere is disclosed. The microsphere includes at least one biodegradable polymer and at least one local anesthetic, wherein about 75% of the at least one local anesthetic is released by about 72 hours and from about 80% to about 90% of the at least one local anesthetic is released by about 120 hours, thereby relieving chronic pain for at least 28 days.

Claims

exact text as granted — not AI-modified
1 .- 18 . (canceled) 
     
     
         19 . A method for treating chronic pain comprising:
 implanting at least one microsphere at a treatment site, the microsphere including poly(lactic-co-glycolic acid) and a plurality of active pharmaceutical ingredients;   wherein about 75% of the plurality of active pharmaceutical ingredients is released by about 72 hours and from about 80% to about 90% of the plurality of active pharmaceutical ingredients is released by about 120 hours; and   relieving chronic pain for at least 28 days.   
     
     
         20 . The method for treating chronic pain according to  claim 19 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 75:25. 
     
     
         21 . The method for treating chronic pain according to  claim 19 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 65:35. 
     
     
         22 . The method for treating chronic pain according to  claim 19 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 50:50. 
     
     
         23 . The method for treating chronic pain according to  claim 19 , wherein the plurality of active pharmaceutical ingredients is released in a substantially linear manner. 
     
     
         24 . The method for treating chronic pain according to  claim 19 , wherein the at least one microsphere is from about 0.001 micrometers to about 1,000 micrometers. 
     
     
         25 . The method for treating chronic pain according to  claim 19 , wherein the at least one microsphere is from about 0.01 micrometers to about 500 micrometers. 
     
     
         26 . The method for treating chronic pain according to  claim 19 , wherein at least one active pharmaceutical ingredient of the plurality of active pharmaceutical ingredients is a local anesthetic. 
     
     
         27 . The method for treating chronic pain according to  claim 26 , wherein the local anesthetic is selected from the group consisting of lidocaine, ropivacaine, procaine, cocaine, benzocaine, bupivacaine, mepivacaine, prilocaine, articaine, tetracaine, dibucaine, chloroprocaine, etidocaine, oxybuprocaine, cocaethylene, dimethocaine, butacaine, proparacaine hydrochloride, proparacaine, piperocaine, hexylcaine, fluorescein, and proparacaine. 
     
     
         28 . The method for treating chronic pain according to  claim 19 , wherein at least one active pharmaceutical ingredient of the plurality of active pharmaceutical ingredients is dexamethasone. 
     
     
         29 . A method for treating chronic pain comprising:
 implanting at least one microsphere at a treatment site, the microsphere formed from including poly(lactic-co-glycolic acid), at least one local anesthetic and at least one active pharmaceutical ingredient other than the at least one local anesthetic;   wherein about 75% of the at least one local anesthetic is released in a substantially linear manner by about 72 hours and from about 80% to about 90% of the at least one local anesthetic is released by about 120 hours; and   relieving chronic pain for at least 28 days.   
     
     
         30 . The method for treating chronic pain according to  claim 29 , wherein the at least one active pharmaceutical ingredient is dexamethasone. 
     
     
         31 . The method for treating chronic pain according to  claim 29 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 75:25. 
     
     
         32 . The method for treating chronic pain according to  claim 29 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 65:35. 
     
     
         33 . The method for treating chronic pain according to  claim 29 , wherein the poly(lactic-co-glycolic acid) includes polylactic acid and glycolic acid at a ratio of about 50:50. 
     
     
         34 . The method for treating chronic pain according to  claim 29 , wherein the at least one local anesthetic is released in a substantially linear manner. 
     
     
         35 . The method for treating chronic pain according to  claim 29 , wherein the at least one microsphere is from about 0.001 micrometers to about 1,000 micrometers. 
     
     
         36 . The method for treating chronic pain according to  claim 29 , wherein the at least one microsphere is from about 0.01 micrometers to about 500 micrometers. 
     
     
         37 . The method for treating chronic pain according to  claim 29 , wherein the at least one local anesthetic is selected from the group consisting of lidocaine, ropivacaine, procaine, cocaine, benzocaine, bupivacaine, mepivacaine, prilocaine, articaine, tetracaine, dibucaine, chloroprocaine, etidocaine, oxybuprocaine, cocaethylene, dimethocaine, butacaine, proparacaine hydrochloride, proparacaine, piperocaine, hexylcaine, fluorescein, and proparacaine.

Join the waitlist — get patent alerts

Track US2020016081A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.